Floatz logo

LBH589

HER-2 Positive Breast Cancer

Novartis PharmaceuticalsPhase 1Dormant
CC
45/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
31/ 100
Competitive Position
89/ 100

Competitive context

12 Active assets in the HER-2 Positive Breast Cancer cohort.

Asset / SponsorPhaseRating
TRASTUZUMAB
National Taiwan University Hospital
Phase 3BB
IMMUNOGLOBULIN G1, ANTI-(HUMAN NEU (RECEPTOR)) (HUMAN-MOUSE MONOCLONAL 2C4 HEAVY CHAIN), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL 2C4 .KAPPA.-CHAIN, DIMER
National Taiwan University Hospital
Phase 3BB
Carboplatin
Instituto do Cancer do Estado de São Paulo
Phase 2/3BB
Inno-206
National Taiwan University Hospital
Phase 2BB
Trastuzumab Emtansine
Dana-Farber Cancer Institute
Phase 2/3BB

View all 25 →

Same molecule, other indications

LBH589 is also rated in:

acute myeloid leukemiaDormant
B
Indicative ·
60 / 100
View asset →
non-Hodgkin lymphomaDormant
CCC
Indicative ·
52 / 100
View asset →
leukemiaDormant
CCC
Indicative ·
52 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →